Literature DB >> 22562111

[Therapeutic targets in arterial hypertension and diabetes mellitus. Can medical prevention be harmful?].

C Chatzikyrkou1, H Haller, J Menne.   

Abstract

Arterial hypertension contributes considerably to the increased cardiorenal risk of patients with diabetes mellitus type 2. Therefore guideline-writing authorities recommend starting antihypertensive treatment generously, with the aim of reducing blood pressure to levels to < 130/80 mmHg. Nevertheless, results of several recent studies have challenged the currently prevailing paradigm "the lower the better" in hypertension management. A similar paradigm also seems to hold true for the management of blood glucose in these patients. Detailed analyses have shown an increased risk of coronary events by targeting both lower blood pressure and blood glucose levels, especially in those with established cardiovascular disease and especially coronary artery disease--thus, the concept of "the lower the better" should be reconsidered in this group of patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22562111     DOI: 10.1007/s00108-012-3071-0

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  52 in total

1.  AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation.

Authors:  Sidney C Smith; Emelia J Benjamin; Robert O Bonow; Lynne T Braun; Mark A Creager; Barry A Franklin; Raymond J Gibbons; Scott M Grundy; Loren F Hiratzka; Daniel W Jones; Donald M Lloyd-Jones; Margo Minissian; Lori Mosca; Eric D Peterson; Ralph L Sacco; John Spertus; James H Stein; Kathryn A Taubert
Journal:  Circulation       Date:  2011-11-03       Impact factor: 29.690

2.  Relation between blood pressure and vascular events and mortality in patients with manifest vascular disease: J-curve revisited.

Authors:  Johannes A N Dorresteijn; Yolanda van der Graaf; Wilko Spiering; Diederick E Grobbee; Michiel L Bots; Frank L J Visseren
Journal:  Hypertension       Date:  2011-11-07       Impact factor: 10.190

3.  Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes.

Authors:  Robert W Schrier; Raymond O Estacio; Anne Esler; Philip Mehler
Journal:  Kidney Int       Date:  2002-03       Impact factor: 10.612

4.  Intensive blood-pressure control in hypertensive chronic kidney disease.

Authors:  Lawrence J Appel; Jackson T Wright; Tom Greene; Lawrence Y Agodoa; Brad C Astor; George L Bakris; William H Cleveland; Jeanne Charleston; Gabriel Contreras; Marquetta L Faulkner; Francis B Gabbai; Jennifer J Gassman; Lee A Hebert; Kenneth A Jamerson; Joel D Kopple; John W Kusek; James P Lash; Janice P Lea; Julia B Lewis; Michael S Lipkowitz; Shaul G Massry; Edgar R Miller; Keith Norris; Robert A Phillips; Velvie A Pogue; Otelio S Randall; Stephen G Rostand; Miroslaw J Smogorzewski; Robert D Toto; Xuelei Wang
Journal:  N Engl J Med       Date:  2010-09-02       Impact factor: 91.245

5.  Relationship between blood pressure and incident chronic kidney disease in hypertensive patients.

Authors:  Rebecca Hanratty; Michel Chonchol; Edward P Havranek; J David Powers; L Miriam Dickinson; P Michael Ho; David J Magid; John F Steiner
Journal:  Clin J Am Soc Nephrol       Date:  2011-09-15       Impact factor: 8.237

6.  Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?

Authors:  Franz H Messerli; Giuseppe Mancia; C Richard Conti; Ann C Hewkin; Stuart Kupfer; Annette Champion; Rainer Kolloch; Athanase Benetos; Carl J Pepine
Journal:  Ann Intern Med       Date:  2006-06-20       Impact factor: 25.391

7.  Effects of intensive blood-pressure control in type 2 diabetes mellitus.

Authors:  William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

8.  Differential impacts of blood pressure and lipid lowering on regression of ventricular and arterial mass: the Stop Atherosclerosis in Native Diabetics Trial.

Authors:  Mary J Roman; Barbara V Howard; Wm James Howard; Mihriye Mete; Jerome L Fleg; Elisa T Lee; Richard B Devereux
Journal:  Hypertension       Date:  2011-07-25       Impact factor: 10.190

9.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

10.  Lowering blood pressure reduces renal events in type 2 diabetes.

Authors:  Bastiaan E de Galan; Vlado Perkovic; Toshiharu Ninomiya; Avinesh Pillai; Anushka Patel; Alan Cass; Bruce Neal; Neil Poulter; Stephen Harrap; Carl-Erik Mogensen; Mark Cooper; Michel Marre; Bryan Williams; Pavel Hamet; Giuseppe Mancia; Mark Woodward; Paul Glasziou; Diederick E Grobbee; Stephen MacMahon; John Chalmers
Journal:  J Am Soc Nephrol       Date:  2009-02-18       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.